CHENGDU, China, July 14, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
Hence then, the article about hitgen partner bioage labs doses first participant in phase 2 trial of bge 102 a novel oral nlrp3 inhibitor for cardiovascular risk reduction was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction )
Also on site :
- Bus crashes into parked cars at Portslade Station
- Longtime ‘Wheel of Fortune’ announcer Jim Thornton suspended after alleged airline incident
- Lori Loughlin Leans on Her ‘Full House’ Family, Including Bob Saget, to Reveal Return to Social Media After 7 Years